RMD ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by ResMed Inc.
NEW YORK, NY / ACCESSWIRE / August 9, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ResMed Inc. ("ResMed") (NYSE:RMD) concerning possible violations of federal securities laws. On August 3, 2023, ResMed reported results for the fourth quarter of fiscal 2023.
ResMed (RMD) is a Top-Ranked Momentum Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
ATTENTION RMD SHAREHOLDERS: Investors who lost money on ResMed Inc. are urged to contact Levi & Korsinsky about an ongoing investigation
NEW YORK, NY / ACCESSWIRE / August 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ResMed Inc. ("ResMed") (NYSE:RMD) concerning possible violations of federal securities laws. On August 3, 2023, ResMed reported results for the fourth quarter of fiscal 2023.
RMD ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by ResMed Inc.
NEW YORK, NY / ACCESSWIRE / August 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ResMed Inc. ("ResMed") (NYSE:RMD) concerning possible violations of federal securities laws. On August 3, 2023, ResMed reported results for the fourth quarter of fiscal 2023.
ResMed Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - RMD
NEW YORK, NY / ACCESSWIRE / August 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ResMed Inc. ("ResMed") (NYSE:RMD) concerning possible violations of federal securities laws. On August 3, 2023, ResMed reported results for the fourth quarter of fiscal 2023.
An Investigation Has Commenced on Behalf of ResMed Inc. Shareholders. Contact Levi & Korsinsky to Discuss your RMD Losses
NEW YORK, NY / ACCESSWIRE / August 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ResMed Inc. ("ResMed") (NYSE:RMD) concerning possible violations of federal securities laws. On August 3, 2023, ResMed reported results for the fourth quarter of fiscal 2023.
ResMed Earnings Reflect Increased Demand For Sleep Devices, Performance Indicates Positive Dynamics, Opportunities
ResMed Inc. RMD reported fourth-quarter 2024 revenue of $1.22 billion, up 9% year-over-year and up 10% on a constant currency basis, in line with the consensus of $1.22 billion.
ResMed's (RMD) Q4 Earnings Surpass Estimates, Margins Expand
ResMed (RMD) delivers solid performance across all regions and business segments in the fourth quarter of fiscal 2024.
Lost Money on ResMed Inc. (RMD)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / August 2, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ResMed Inc. ("ResMed") (NYSE:RMD) concerning possible violations of federal securities laws. On August 3, 2023, ResMed reported results for the fourth quarter of fiscal 2023.
ResMed Inc. (RMD) Q4 2024 Earnings Call Transcript
ResMed Inc. (NYSE:RMD ) Q4 2024 Earnings Conference Call August 031, 2024, 04:30 PM ET Company Participants Amy Wakeham - Chief Communications and Investor Relations Officer Michael Farrell - Chief Executive Officer Brett Sandercock - Chief Financial Officer Conference Call Participants Lyanne Harrison - Bank of America Steven Wheen - Jarden Brett Fishbin - KeyBanc Michael Matson - Needham & Company Dan Hurren - MST Marquee David Bailey - Macquarie Gretel Janu - E&P Suraj Kalia - Oppenheimer Margaret Kaczor-Andrew - William Blair Anthony Petrone - Mizuho Group Saul Hadassin - Barrenjoey Capital Operator Hello, and welcome to the Q4 Fiscal Year 2024 ResMed Earnings Conference Call. My name is Kevin, and I'll be your operator for today's call.
Compared to Estimates, ResMed (RMD) Q4 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for ResMed (RMD) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
ResMed (RMD) Beats Q4 Earnings and Revenue Estimates
ResMed (RMD) came out with quarterly earnings of $2.08 per share, beating the Zacks Consensus Estimate of $2.03 per share. This compares to earnings of $1.60 per share a year ago.
